Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of acute ischemic stroke.

Phillip Scott1

  • 1Department of Emergency Medicine, University of Michigan, Ann Arbor, USA. phlsctt@umich.edu

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed
Summary

Intravenous thrombolytic therapy for acute ischemic stroke is underutilized despite proven efficacy. Optimizing critical care and systems is essential for improving patient outcomes and stroke treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-12 mRNA-LNP promotes dermal resident memory CD4<sup>+</sup> T cell development.

NPJ vaccines·2025
Same author

An <i>Il12</i> mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses.

Science immunology·2025
Same author

Staphylococcus aureus promotes strain-dependent immunopathology during cutaneous leishmaniasis through induction of IL-1β.

Cell reports·2025
Same author

A Quantitative Polymerase Chain Reaction (qPCR) Protocol Predictive of Treatment Outcome in Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i>.

Open forum infectious diseases·2025
Same author

What's the bug?: An unusual cause of bacterial meningitis in a patient with history of transsphenoidal surgery.

The American journal of emergency medicine·2025
Same author

Malnutrition disrupts adaptive immunity during visceral leishmaniasis by enhancing IL-10 production.

PLoS pathogens·2024

Area of Science:

  • Neuroscience
  • Emergency Medicine
  • Critical Care

Background:

  • No proven therapy existed for acute ischemic stroke before 1995.
  • Intravenous recombinant tissue plasminogen activator (rt-PA) was approved in 1996 for acute stroke treatment.
  • Despite approval, thrombolytic treatment remains underutilized in 1-2% of stroke patients.

Purpose of the Study:

  • To review the pathogenesis of cellular injury in stroke.
  • To focus on data involving thrombolytic reperfusion therapy.
  • To highlight post-thrombolytic critical care issues and secondary stroke prevention.

Main Methods:

  • Review of existing literature on acute ischemic stroke.
  • Analysis of data concerning thrombolytic reperfusion therapy.
  • Discussion of critical care management, complications, and prevention strategies.

Main Results:

  • Recombinant tissue plasminogen activator (rt-PA) is an effective therapy for acute ischemic stroke.
  • Significant underutilization of rt-PA highlights a gap in acute stroke care delivery.
  • Critical care management significantly impacts patient outcomes following thrombolytic therapy.

Conclusions:

  • Organizing systems for time-urgent acute stroke care is crucial.
  • Critical care specialists play a vital role in managing stroke patients, especially post-thrombolysis.
  • Effective secondary prevention and complication management are essential for improving overall stroke patient care.

Related Experiment Videos